TGF-β expression in the tumor and its circulating levels and activity of TGF-β downstream signaling molecules often increase during cancer progression, and these levels are correlated with aggressive tumor phenotypes such as increased grade and advanced stage [157,158]. This evidence concerns the gene TGFB1 and cancer.